ArticleObesity surgery2026
Prophylactic Tranexamic Acid as Prevention for Early Postoperative Bleeding after Roux-en-Y Gastric Bypass.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative bleeding (POB) after Roux-en-Y gastric bypass (RYGB) occurs in up to 4.1% of cases and is associated with increased 30-day mortality, transfusions, and reinterventions.
methodsThis study evaluated whether tranexamic acid (TXA) administered during anesthetic induction reduces clinical POB within 48 h after primary laparoscopic RYGB. Secondary outcomes included risk factors for POB, thromboembolic events (TEE), and mortality. In this mixed cohort study, consecutive patients undergoing RYGB between 2020 and 2025 were divided according to systematic TXA use.
resultsAmong 678 patients, 347 (51.2%) received TXA. This group’s mean age was 37 years and their mean BMI 40.4 kg/m². POB occurred in 21 patients (3.1%). TXA significantly reduced POB risk (OR 4.25; p = 0.007). Being of male sex increased POB risk (OR 2.59; p = 0.031). No differences in TEE or mortality were observed.
conclusionsTXA reduced POB risk by 70–78%. It was also noted that male sex was an independent risk factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.